Skinner L G, Barnes D M, Ribeiro G G
Cancer. 1980 Dec 15;46(12 Suppl):2939-45. doi: 10.1002/1097-0142(19801215)46:12+<2939::aid-cncr2820461440>3.0.co;2-5.
Measurement of cytoplasmic estrogen (REc) and progesterone (RPc) receptors in human breast tumors together with estrogen receptor activity in the residual pellet ("nuclear" REN) provides a more accurate prediction of hormonal dependence that REc alone. Of 74 patients with advanced metastatic breast cancer, 57% of those with REc+ tumors had an objective response to endocrine manipulation. Of 51 patients whose tumor was assayed for both REc and RPc activity, 9 of 12 patients with REc+ RPc+ tumors showed remission, whereas only 3 of 30 patients with REc- RPc-, 2 of 6 with REc+ RPc-, and 2 of 3 with REc- RPc+ tumors had a clinical response. In a group of 19 patients where triple assay was performed, 5 of 6 with tumors positive for all three receptors responded, whereas 9 patients with triple negative tumors all showed no remission. Fifty-nine percent of primary and 60% of metastatic tumors with REc+ activity were also shown to be RPc+. Thirteen percent of REc- tumors were RPc+. Patients with REc+ RPc+ primary tumors tended to have a longer disease-free interval than patients with RPc- tumors, irrespective of whether the tumors were REc+ or REc-. In the light of the possibility of employing receptor status of the primary tumor to predict hormonal responsiveness in subsequent recurrences, a comparison is made of receptor status measured in primary tumors and metastases.
对人类乳腺肿瘤中的细胞质雌激素（REc）和孕激素（RPc）受体进行测量，同时测量残余沉淀物中的雌激素受体活性（“核”REN），比单独测量REc能更准确地预测激素依赖性。在74例晚期转移性乳腺癌患者中，REc阳性肿瘤患者中有57%对内分泌治疗有客观反应。在51例对肿瘤进行了REc和RPc活性检测的患者中，12例REc阳性且RPc阳性肿瘤患者中有9例出现缓解，而30例REc阴性且RPc阴性肿瘤患者中只有3例、6例REc阳性且RPc阴性肿瘤患者中有2例、3例REc阴性且RPc阳性肿瘤患者中有2例有临床反应。在一组19例进行三联检测的患者中，6例所有三种受体均为阳性的肿瘤患者中有5例有反应，而9例三联阴性肿瘤患者均未出现缓解。REc阳性的原发性肿瘤和转移性肿瘤中，分别有59%和60%也显示为RPc阳性。REc阴性的肿瘤中有13%为RPc阳性。REc阳性且RPc阳性的原发性肿瘤患者的无病生存期往往比RPc阴性肿瘤患者更长，无论肿瘤是REc阳性还是REc阴性。鉴于利用原发性肿瘤的受体状态来预测后续复发时激素反应性的可能性，对原发性肿瘤和转移灶中测量的受体状态进行了比较。
